Program
trastuzumab pamirtecan
Also written as “DB-1303/BNT323”, “BNT323/DB-1303” and “BNT323”.
Its studies are mostly in Breast Neoplasms · Endometrial Neoplasms · Neoplasm Metastasis, led by 2 companies.
Drug pageTrastuzumab pamirtecan: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| DualityBioits history only | 33 open or running | phase 3since Aug 25, 2023 | Nov 11, 2021 | Aug 2027phase 2 · NCT05150691 |
| BioNTech | 22 open or running | phase 3since Mar 25, 2024 | Mar 25, 2024 | Mar 2028phase 3 · NCT06340568 |
Also a collaborator on its studies: BioNTech (Shanghai) Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of BioNTech only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Mar 25, 2024First study: phase 3 study in Endometrial NeoplasmsFirst studyNCT06340568 · 480 planned · United States, Argentina, Australia and more
- Aug 11, 2024Named trastuzumab pamirtecanINNProposed as its International Nonproprietary Name in WHO's List 131 · before, BNT323
- Feb 10, 2025Phase 2 study in Breast NeoplasmsNCT06827236 · 380 planned · United States, Australia, Canada and more
Ahead
- Mar 2028Primary completion: phase 3 study in Endometrial NeoplasmsNCT06340568
- Aug 2029Primary completion: phase 2 study in Breast NeoplasmsNCT06827236
TargetBeta
“An antibody-drug conjugate (ADC) composed of trastuzumab, a humanized monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), ”NCIt, by rule
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Trastuzumabrule | Hoffmann-La Roche | phase 4 | 85 |
| pertuzumabrule | Hoffmann-La Roche | phase 4 | 56 |
| trastuzumab deruxtecanrule | Daiichi Sankyo | phase 4 | 49 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
All 2 BioNTech leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06827236Breast Neoplasms · United States, Australia, Canada and more | 2 | Recruiting | Aug 2029 | 380 |
| NCT06340568Endometrial Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Mar 2028 | 480 |
How it is read
Names in the registry
- “DB-1303/BNT323”, 3 entries
- “BNT323/DB-1303”, 1 entry
- “BNT323”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 3 studies
- Endometrial Neoplasms, 1 study
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.